Publications by authors named "Claudepierre P"
Objectives: To evaluate the effectiveness of short message service (SMS) and/or email reminders in improving influenza vaccination coverage rates among rheumatoid arthritis (RA) patients treated with anti-TNF therapies, and to identify factors associated with vaccination.
Methods: A nested randomized controlled trial in the ART e-cohort, an ongoing French nationwide multicentre prospective cohort of RA patients treated with anti-TNF therapy. Patients were 1:1 randomized, with stratification on age.
Article Synopsis
- This study aimed to explore the dietary practices and beliefs of patients with rheumatic and musculoskeletal diseases, focusing on how these factors affect their symptoms.
- It involved a survey of 392 patients, revealing that 26% had tried exclusion diets, with only 5% adhering to the Mediterranean diet, while many reported dietary changes could reduce their pain.
- Results indicate that health beliefs and the lack of dietary guidance from healthcare providers play significant roles in patients' dietary choices and perceptions of their diets' effects on pain.
Objectives: To assess the potential impact of targeted therapies for psoriatic arthritis (PsA) on symptomatic treatments (non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, opioid analgesics), methotrexate and mood disorder treatments and on hospitalisation and sick leave.
Methods: Using the French health insurance database, this nationwide cohort study included adults with PsA who were new users (not in the year before the index date) of targeted therapies for ≥9 months during 2015-2021. Main endpoints were difference in proportion of users of associated treatments, hospitalisations and sick leaves between 3 and 9 months after and 6 months before targeted therapy initiation.
Background: Inception cohorts aim to describe chronic diseases from diagnosis and over years of follow-up. Axial spondyloarthritis (axSpA) diagnosis might be challenging during the first years of the disease. Thus, identifying the features that will be associated with a confirmed diagnosis over time is key.
View Article and Find Full Text PDFThe progress observed over the last 30 years in the field of axial spondyloarthritis (axSpA) has not made it possible to answer all the current questions. This manuscript represents the proceedings of the meeting of the French spondyloArthitiS Task force (FAST) in Besançon on September 28 and 29, 2023. Different points of discussion were thus individualized as unmet needs: biomarkers for early diagnosis and disease activity, a common electronic file dedicated to SpA nationwide, a better comprehension of dysbiosis in the disease, a check-list for addressing to the rheumatologist, adapt patient reported outcomes thresholds for female gender, implementation of comorbidities screening programs, new imaging tools, in research cellular and multi omics approaches, grouping, at a nationwide level, different cohorts and registries, therapeutic strategy studies, consensual definition of difficult to treat disease and management, preclinical stage of the disease, mastering AI as a tool in the various aspects of research.
View Article and Find Full Text PDFIntroduction: National and international scientific societies advocate for a regular, systematic, and standardized global evaluation of axial spondyloarthritis (axSpA) patients. However, there are no recommendations specifying the content of this global evaluation. This initiative aimed to propose a standardized reporting framework, using evidence-based and consensus approaches, to collect data on all domains of axSpA.
View Article and Find Full Text PDFObjective: New modes of action and more data on the efficacy and safety of existing drugs in psoriatic arthritis (PsA) required an update of the EULAR 2019 recommendations for the pharmacological treatment of PsA.
Methods: Following EULAR standardised operating procedures, the process included a systematic literature review and a consensus meeting of 36 international experts in April 2023. Levels of evidence and grades of recommendations were determined.
Article Synopsis
- - The objective of the study was to evaluate the risk of serious infections in patients with psoriatic arthritis who were starting various targeted therapies in real-world scenarios.
- - Researchers analyzed data from over 12,000 patients and found that 3% experienced serious infections, with a notable difference in infection rates depending on the therapy used, particularly lower rates for etanercept and ustekinumab compared to adalimumab.
- - The study concluded that the overall risk of serious infections is relatively low for patients on targeted therapies for PsA, but newer users of etanercept and ustekinumab had a significantly reduced risk compared to those starting adalimumab, while the other treatments did not show significant differences.
Objective: To compare the 1-year retention rate of secukinumab in axial spondyloarthritis (axSpA) and its predisposing factors with regard to its time of initiation (eg, right after or remotely from its launch).
Methods: Study design: Retrospective multicentre French study of patients with axSpA. Study periods: Two cohorts were evaluated regarding the time of initiation of secukinumab: cohort 1 (C1)-between 16 August 2016 and 31 August 2018-and cohort 2 (C2)-between 1 September 2018 and 13 November 2020.
Article Synopsis
- - The study compares the ability of MRI and radiographs to detect erosions in the sacroiliac joint (SIJ) for patients with recent-onset axial spondyloarthritis (axSpA) over a 104-week period, with a focus on the effects of the treatment etanercept. - Results showed that MRI detected more erosions than radiographs at baseline and in changes over time, with a significant number of patients demonstrating improved erosion scores on MRI compared to radiographs after treatment. - The research highlights that MRI may be superior in monitoring SIJ erosions in axSpA, suggesting that further investigation into the clinical significance of these findings is needed.
Objectives: This study aimed to evaluate the 10-year clinical outcome of patients with recent-onset axial spondyloarthritis (axSpA).
Methods Study Design: The DESIR cohort is an inception cohort of axSpA patients.
Methods Diagnosis And Management: The diagnosis and management of patients were based on the decision of the treating rheumatologist.
Background: Sex differences in phenotype presentation, disease trajectory and treatment response in psoriatic arthritis (PsA) have been reported. Nevertheless, whether classes of targeted therapies differentially affect men and women with PsA remains unclear.
Objectives: To assess the effect of sex on the long-term persistence of each class of targeted therapies in PsA.
Objective: To assess whether the presence of bone marrow edema (BME) leads to the development of structural lesions at the same anatomical location of the sacroiliac joints (SIJ), and to investigate the association between BME patterns over time and structural lesions in patients with early axial spondyloarthritis (axSpA).
Methods: Patients with axSpA from the DESIR cohort with ≥2 consecutive magnetic resonance imaging (MRI)-SIJ were assessed at baseline, 2 and 5 years. MRI-SIJ images were divided into 8 quadrants.
Background: Secukinumab efficacy and retention data are emerging in patients with axial spondyloarthritis (axSpA) in real-world settings. However, limited data are available on the predictive factors that affect the retention rate. The key objective was to determine whether objective signs of inflammation (OSI) were predictive of secukinumab retention at 1 year.
View Article and Find Full Text PDFArticle Synopsis
- Tumour necrosis factor inhibitors (TNFi) are the first treatment for people with psoriatic arthritis (PsA), but sometimes doctors need to switch medications.
- A study looked at how long patients stuck with different biologic treatments after stopping a TNFi.
- Results showed that after 3 years, patients using other treatments like IL-17 or IL-12/23 inhibitors stayed on their meds longer than those using TNFi.
Objective: To develop and validate a patient knowledge questionnaire regarding axial spondyloarthritis (axSpA).
Methods: Knowledge considered essential for patients with axSpA was identified through Delphi rounds among rheumatologists, healthcare professionals (HCPs), and patients, then reformulated to develop the knowledge questionnaire. Cross-sectional validation was performed in 14 rheumatology departments to assess internal validity (Kuder-Richardson coefficient), external validity, acceptability, reproducibility (Lin concordance correlation coefficient), and sensitivity to change (knowledge score before vs after patient education sessions and effect size).
Background: Paradoxical reactions (PRs) are defined as the occurrence during biologic therapy of a pathological condition that usually responds to these drugs.
Objectives: To estimate the incidence of PRs and identify risk factors.
Methods: Multicentre study of the database for the Greater Paris University Hospitals, including biologic-naive patients receiving anti-tumour necrosis factor-α, anti-interleukin-12/23, anti-interleukin-17 or anti-α4β7-integrin agents for psoriasis, inflammatory rheumatism or inflammatory bowel disease (IBD).
Article Synopsis
- A retrospective study evaluated the safety of three JAK inhibitors (ruxolitinib, tofacitinib, baricitinib) using data from the WHO database, focusing on their associated adverse events.
- The analysis found a significant link between these drugs and various adverse events, particularly infectious diseases, musculoskeletal issues, and certain cancers, with ruxolitinib showing a notable risk for viral, fungal, and mycobacterial infections.
- Tofacitinib was specifically associated with gastrointestinal perforations, while no significant increase in major cardiovascular events was reported across the drugs studied.